Diagnostic value of 11C-metomidate Positron Emission Tomography/Computerized Tomography (PET/CT) for the evaluation of primary aldosteronism: a pilot study

Diagnostic value of 11C-metomidate Positron Emission Tomography/Computerized Tomography (PET/CT) for the evaluation of primary aldosteronism: a pilot study - PET/CT in primary aldosteronism

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35185

Enrollment

Registered

2010-03-03

Start date

2010-03-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary aldosteronism - Conn's syndrome - overactive adrenal gland with excessive secretion of aldosterone

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - adult subjects (at least 18 years of age) - primary aldosteronism with complete diagnostic work-up including succesfully performed adrenal venous sampling

Exclusion criteria

Exclusion criteria: - diabetes melltus (type 1 or type 2) - use of ketoconazole, metyrapone or cytostatic drugs in previous 6 months - pregnancy - severe contrast allergy - serious comorbidities precluding surgery Note: last 3 conditions are exclusion criteria for adrenal venous sampling, not for 11C-metomidate PET/CT

Design outcomes

Primary

Measure	Time frame
To establish with PET whether 11C-metomidate is selectively taken up by adrenal gland tissue with autonomic hypersecretion of aldosterone and that the distribution of tracer uptake by the adrenal glands (unilateral versus bilateral) is concordant with the results of AVS. Results are presented as percentages with 95%-confidence intervals.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results